Jim Healy, Sofinnova managing partner
Sofinnova’s Jim Healy on ‘more rational market’ as four biotech startups near their IPOs
In what’s shaping up to be another slow year for biotech IPOs — better, however, than the 2022 and 2023 doldrums — Jim Healy is somewhat of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
